Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTS109 in Moderate to Severe Refractory Autoimmune Diseases
NCT07526350Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Lipid-based Nanoparticles, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTS-109 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and 2 more, sponsored by Shanghai Changzheng Hospital. Primary endpoints: Incidence of adverse events of Grade >=3 and Incidence of treatment-emergent adverse events. Started Mar 2026; status: recruiting.
02
Drugs
MTS-109
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07526350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526350.